Want to see FR:IPN full AI Analyst Report?
IPN Stock Chart & Stats
€161.80
€0.40(0.34%)
At close: 4:00 PM EST
€161.80
€0.40(0.34%)
Day’s Range― - ―
52-Week Range€101.20 - €173.50
Previous CloseN/A
Volume2.80K
Average Volume (3M)64.26K
Market Cap
€14.12B
Enterprise Value€12.49B
Total Cash (Recent Filing)€1.53B
Total Debt (Recent Filing)€867.10M
Price to Earnings (P/E)31.9
Beta0.53
Next Earnings
Jul 30, 2026EPS Estimate
6.3Next Dividend Ex-DateN/A
Dividend Yield1.17%
Share Statistics
EPS (TTM)5.37
Shares Outstanding83,814,530
10 Day Avg. Volume52,964
30 Day Avg. Volume64,259
Financial Highlights & Ratios
PEG Ratio0.78
Price to Book (P/B)2.29
Price to Sales (P/S)2.70
P/FCF Ratio9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€164.80Price Target Upside1.85% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)13.02
Revenue Forecast (FY)€4.25B
Bulls Say, Bears Say
Bulls Say
Steady Revenue Growth & ProfitabilitySustained multi-year top-line growth with a ~30% EBITDA margin indicates a scalable specialty-biopharma model and durable demand for marketed therapies. Over 2–6 months this underpins cash generation, reinvestment capacity, and supports continued commercial and R&D investment.
Improved Free Cash Flow GenerationA strong FCF rebound with FCF closely matching net income signals higher quality earnings and improved internal funding capacity. Durable cash generation enhances ability to fund pipeline, partnerships, and capital allocation without excessive external financing over the medium term.
Conservative Capital Structure (Low Leverage)Low leverage and rising equity provide balance-sheet resilience and financial flexibility to support R&D, M&A, or weather reimbursement cycles. Structurally, this positions the company to absorb shocks and pursue strategic investments without immediate refinancing pressure.
Bears Say
Meaningful Margin CompressionA sustained decline in net margins versus prior years suggests persistent cost pressures, pricing/reimbursement headwinds, or adverse product mix. Over months this reduces incremental returns on new investments, compresses internal funding for R&D, and limits profit resilience.
Sharp Increase In Total Debt (2025)A sudden rise in debt raises structural financing and interest-rate exposure, reducing cushioning for adverse outcomes. With returns on equity trending lower, incremental leverage may strain flexibility for strategic initiatives and heighten refinancing risk over the medium term.
Volatile Cash ConversionInconsistent operating-to-free-cash conversion creates execution and working-capital risk, complicating reliable funding of R&D and debt service. Structural volatility means management must continually manage liquidity, which can limit confident multi-quarter planning and capital allocation.
IPN FAQ
What was Ipsen’s price range in the past 12 months?
Ipsen lowest stock price was €101.20 and its highest was €173.50 in the past 12 months.
What is Ipsen’s market cap?
Ipsen’s market cap is €14.12B.
When is Ipsen’s upcoming earnings report date?
Ipsen’s upcoming earnings report date is Jul 30, 2026 which is in 26 days.
How were Ipsen’s earnings last quarter?
Ipsen released its earnings results on Feb 12, 2026. The company reported €6.02 earnings per share for the quarter, beating the consensus estimate of €5.527 by €0.493.
Is Ipsen overvalued?
According to Wall Street analysts Ipsen’s price is currently Undervalued.
Does Ipsen pay dividends?
Ipsen pays a Annually dividend of €1.6 which represents an annual dividend yield of 1.17%. See more information on Ipsen dividends here
What is Ipsen’s EPS estimate?
Ipsen’s EPS estimate is 6.3.
How many shares outstanding does Ipsen have?
Ipsen has 83,814,530 shares outstanding.
What happened to Ipsen’s price movement after its last earnings report?
Ipsen reported an EPS of €6.02 in its last earnings report, beating expectations of €5.527. Following the earnings report the stock price went up 6.34%.
Which hedge fund is a major shareholder of Ipsen?
Currently, no hedge funds are holding shares in FR:IPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ipsen
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.
IPN Stock 12 Month Forecast
Average Price Target
€164.80
▲(1.85% Upside)
Technical Analysis
Options Prices
Currently, No data available
---